Navegando por Palavras-chave "Drugs, generic"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Diferenças de preços entre medicamentos genéricos e de referência no Brasil
    (Faculdade de Saúde Pública da Universidade de São Paulo, 2006-06-01) Vieira, Fabiola Sulpino [UNIFESP]; Zucchi, Paola [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    OBJECTIVE: To assess the magnitude of price difference between generic and innovator medicines and to evaluate the effect of the price competition between them. METHODS: From January 2000 to June 2004, 135 generic medicines and their respective innovator medicines were followed up for a period of up to four years. Prices were extracted from pharmaceutical market specific publications and recorded from the launching of generics and during their marketing period. RESULTS: The generic medicines were introduced on average at prices 40% lower than the innovator ones and this difference tended to increase over the years. The price difference between generic and innovator medicines increased in the subsequent four-year period after generic launching in 68%. CONCLUSIONS: The introduction of generic medicines in the Brazilian pharmaceutical market contributed for offering cheaper medicines. However, the competition between generic and innovator medicines did not promote markdown of the majority innovator medicines.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Participação dos quimioterápicos genéricos no mercado de saúde suplementar brasileiro: caso autogestão
    (Universidade Federal de São Paulo (UNIFESP), 2009-11-26) Campos, Vilma Suely Lopes [UNIFESP]; Araujo, Denizar Vianna [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Objective: To quantify the market share of the generic chemotherapeutic drugs in a Self-Managed Healthcare Plan Service. Methods: Manual survey of featured bills charging the chemotherapeutic treatments applied to the participants of “CASSI – Caixa de Assistência de Funcionários do Banco do Brasil”;/Assistance relief of the Banco do Brasil employees;/in the states of São Paulo e Rio de Janeiro in the period of July/2004 to February/2005 inclusively, totalizing 228.555 beneficiaries and involving a web of 12.912 service providers, who only 90 had agreements to services focused on oncology, included chemotherapy. Result: From the 1.177.050 featured bills, only 81.097 derived from the service providers included in the study, that is, holding agreements to chemotherapeutic treatment. As these service providers weren’t just experts on Oncology, but usually also general hospitals, the number of bills concerning about the chemotherapy services was reduced to 3.401, which constitutes the universe of our study. These payable documents charged 129 distinct medicines in 11.394 registers, for 70 distinct active principles. The market share of the generic chemotherapeutic was rated in 0,53% considering the charged value, and 1.52% considering the quantity of charged medications. The Reference medications occupied the second place in the market share, with regard to quantity, with 35,39% and the Similar medications, in first place, with 63,09% of the charged medications. Conclusion: Despite the availability of the Generic chemotherapeutic drugs, their market share was not expressive on the bills presented by the service providers. We verified the market share of the Generic chemotherapeutic in 1,5% if considering the quantity of medications, and 0,5 if considering the value. It’s important a bigger participation of the Healthcare Plan Service on the responsible decision about the indicated treatment, as well as the participator’s. In terms, the chaos, which had already been foreseen, aggravates itself, for the resources are also limited to Health.